A Comprehensive Review of Agranulocytosis
1. Karan Karwe
2. Arslan Latif
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Agranulocytosis is acknowledged as a serious condition and is defined as the absolute neutrophil count (ANC) falling down to less than 500 cells/L, thereby constituting a hematological emergency. This complete review, through a systematic approach, presents the current academic knowledge in a synthesized form and gives a major emphasis on drug-induced agranulocytosis (DIAG), which is the most prevalent acquired type in adults. The IMRAD structure has been followed in the writing of this article, which goes into the intricate etiological landscape, elucidating the pathophysiological dichotomy between immune-mediated and direct myelotoxic mechanisms. It highlights the clinical picture consisting of the sudden emergence of fever and loss of immunity resulting from the bacterial or fungal infections that occur as a consequence of lost innate immunity. Diagnostic procedures that stress the urgent performance of complete blood count (CBC) and careful review of medications are recommended. The management paradigm that is supported by clinical evidence is based on the immediate withdrawal of the agent responsible for the condition, rapid start of broad-spectrum antimicrobial therapy and the judicious use of granulocyte colony-stimulating factor (G-CSF) to cut short the period of neutropenia. Modern supportive care has led to drastic improvement in prognostic outcomes; however, mortality is still significant in cases with delayed presentation, old age or septic complications. Through this review, the author(s) intend to consolidate recent research, point out changing ideas in pharmacogenomics, and emphasize the importance of doctor’s alertness and patient education in lessening the risks linked to this severe adverse drug reaction.
Keywords: Agranulocytosis, Neutropenia, Drug-Induced, Idiosyncratic Reaction,
Granulocyte Colony-Stimulating Factor (G-CSF), Neutrophil, Myelotoxicity, Pharmacogenomics, Hematological Emergency.
INTRODUCTION
Agranulocytosis is one of the bone marrow failures that lead to the most serious consequences, and it is particularly marked by the total annihilation of circulating neutrophils, the primary cellular warriors of the human body against bacterial and fungal infections. The condition is medically defined by an absolute neutrophil count (ANC) of under 500 cells/µL, often going down to levels less than 100 cells/µL. As a result, a patient enters a state of considerable immunological deficiency (Andr´es et al., 2022). In clinical terms, this condition results in a dramatic increase in the risk of experiencing heavy and fast- growing infections that can quickly lead to sepsis, which may be a fatal condition. The term ”agranulocytosis” itself, which consists of Greek root words that mean ”without granulocytes,” illustrates in a precise manner the dangerous gap that has been created in the innate immune system.
The historical path of the agranulocytosis concept is very much connected with the modern pharmacology breakthrough. During the 1920s and 1930s, numerous cases were reported due to the use of the painkiller amidopyrine, which was a drug responsible for the first clear identification of a drug as the causative agent (Kaufman and Kogulan, 2001). These cases formed the basis for the idea of idiosyncratic drug reactions—unpredictable, non-dose-dependent adverse effects caused by the particular susceptibility of the patients. At present, drug-induced agranulocytosis (DIAG) is considered the main cause in adults, representing about 70-80% of all cases and having an annual incidence of 2.4-15.4 cases per million population (Strom et al., 2012; Curtis, 2014). Interestingly, the epidemiological studies show that women have a higher incidence rate, and the age factor has a significant role in the incidence as it is observed that the older the age, the higher the incidence is, which is probably due to greater medication exposures, polypharmacy, and possibly age- related changes in drug metabolism and immune regulation.
Beyond the realm of DIAG, a wide range of causes can still be considered. Amongst these, autoimmune diseases like Felty’s syndrome (where rheumatoid arthritis is combined with enlarged spleen) and systemic lupus erythematosus (SLE) are able to lead to the destruction of neutrophils that are mediated by the immune system. Alongside, some viral infections (like Ebola, HIV, parvovirus B19) are suspected to do the same by either making the bone marrow less efficient or destroying the cells in the periphery. It is commonly assumed that primary autoimmune neutropenia is a leading factor in infants and toddlers. Besides that, a lack of essential nutrients (vitamin B12, folate) can severely affect one’s health and cause the infiltration of hematological malignacies (acute leukemias, myelodysplastic syndromes) to the bone marrow and genetic disorders such as Kostmann syndrome make up the complete list of differential diagnoses.
The therapeutic and clinical importance of agranulocytosis is huge. It creates a picture of the maximum level of severe and unpredictable drug reaction which can be very hard to handle when it comes to drug development, regulatory safety monitoring, and clinical risk-benefit analysis. The forced blood count monitoring protocols of drugs like clozapine show how serious this risk is. For doctors, it poses a condition of sharpness in diagnosis since its symptoms could be that of a patient having infection which is however not the case and requires specialized and very time-sensitive treatment.
This review has the purpose of giving the most complete and the most academically rigorous possible overview of agranulocytosis. It will, step by step, look at the causes of the phenomenon that are multiple in nature, shed light on the molecular and cellular mechanisms supporting neutrophil loss, and discuss the basic clinical and diagnostic fea- tures and finally, critically assess the modern-day management options on the basis of the latest evidence. It will also speak of prognostic factors and future directions in the area of prevention and treatment. The intention is to produce a unified reference that connects the findings of the past and present ones.
METHODS
This paper is like a comprehensive narrative systematic review with a lot of depth and it is also intended to thoroughly synthesize and critically evaluate the literary works existing on agranulocytosis. To maintain a high level of academic quality and reproducibility, a formalized search and selection method was applied.
Literature Search Strategy
The systematic electronic search was performed on three major databases, namely, PubMed/MEDLINE, Scopus, and Web of Science. The publications included from January 1990 to March
2024 in the search timeframe were meant to be such that both groundbreaking works and cutting-edge advancements were captured. The search method applied a mixture of Med- ical Subject Headings (MeHSH) terms and free-text keywords to get the highest possible sensitivity. The main search terms were: ”agranulocytosis,” ”severe neutropenia,” ”drug- induced neutropenia,” ”idiosyncratic drug reaction,” ”granulocyte colony-stimulating fac- tor,” ”filgrastim,” ”neutrophil,” and ”myelotoxicity.” These were interconnected with Boolean operators (AND, OR) and adapted separately for each database. For instance, PubMed had the search string as: (”Agranulocytosis”[Mesh] OR ”Neutropenia”[Mesh]) AND (”Chemically Induced”[Mesh] OR ”Drug-Related Side Effects and Adverse Reactions”[Mesh] OR ”G-CSF”[Mesh]).
Study Selection and Eligibility Criteria
The records that were identified underwent a two-phase procedure of screening consisting of title/abstract along with subsequent full-text review. The criteria for inclusion were based on:
Meta-analyses and systematic reviews.
Randomized controlled trials (RCTs) primarily focusing on G-CSF therapy.
Significant prospective and retrospective cohort studies yielding epidemiological or outcome data.
Major hematology societies’ (like American Society of Hematology, European Society for Medical Oncology) clinical practice guidelines.
Mechanistic in vitro and in vivo studies of a high impact making elucidation of the pathogenic pathways.
On the other hand, case reports and small case series were included in a selective manner to demonstrate rare etiologies, novel mechanisms, or unusual clinical presentations that had not been addressed in larger studies. Publications written in a language other than English, dealing exclusively with animal models without any human translational relevance, or being editorials/commentaries without original data were eliminated from the selection.
Data Extraction and Synthesis
From each of the studies chosen, data was taken out and put into a common template that included: the design and the population of the study, the causative agents (for DIAG), the suggested mechanisms, the diagnostic methods, the therapeutic interventions (antibiotics, G-CSF type/dose/duration), and the clinical outcomes (time to neutrophil recovery, infection resolution, and mortality). Any differences in the data that had been taken out were sorted through talks and the source material being re-reviewed. Due to the diversity in the study designs and populations (which made a formal meta-analysis impossible) a narrative synthesis was done. The findings were classified thematically ac- cording to the IMRAD structure. The evidence was weighted, giving priority to data coming from RCTs and large, well-controlled observational studies. Tables were designed to make the complex information, such as drug risk categories and comparative management recommendations, easily understandable.
RESULTS
Etiology and Epidemiology: A Detailed Landscape
The causation of agranulocytosis is best understood through a detailed taxonomy. Drug- induced cases are paramount, but a thorough differential diagnosis is essential.
Epidemiology: Studies on a population basis have given essential information about the risks. The International Agranulocytosis and Aplastic Anemia Study (IAAAS) is still a landmark, which has estimated a total annual incidence of non-chemotherapy DIAG of 3.4-5.4 cases per million (Strom et al., 2012). Cortical studies in Europe are suggesting higher rates, even up to 15.4 cases per million, probably because of better detection or changes in drug usage (André’s et al., 2019). The risk increases drastically with age, with those over 65 years old having 5-10 times more new cases than younger adults. There is a consistent higher proportion of females (˜2:1) and the causes for this are probably the combination of various factors, such as the influence of hormones on immune system function, body composition differences which alter drug metabolism, and possibly the use of more drugs belonging to the group that includes the affected ones.
High-Risk Drugs: Among the commonly prescribed drugs clozapine is the one with the highest absolute risk, which is estimated at around 0.8% in the first year and thus necessitates a stringent risk evaluation and mitigation strategy which includes white blood cell monitoring (Alvir et al., 1993). The antithyroid drugs (thionamides) such as carbimazole and methimazole are the drugs which are highly risky, and the risk is estimated to be 0.2-0.5% constantly over time, unlike the case of clozapine where the risk declines after the first six months. Dipyrone (metamizole), a very strong NSAID that has been banned in some countries but is still available in others, is also a well-known offender. The antibiotic sulfamethoxazole/trimethoprim and the anti-platelet medications ticlopidine and clopidogrel are also other important but less frequent causes.
Pathogenesis: Molecular and Cellular Mechanisms
Understanding the pathogenesis requires distinguishing between the two-primary path- ways in DIAG and contrasting them with other causes.
Immune-Mediated Drug-Induced Agranulocytosis
This is the typical idiosyncratic reaction. The mechanism encompasses three main events:
Haptenization/Prohapten Formation: The original drug (for instance, clozapine) gets converted, mostly by neutrophil myeloperoxidase, into a highly reactive nitrenium ion or some other electrophilic metabolite. The reactive metabolite binds to the proteins on the surface of neutrophils or their progenitors in the bone mar- row (especially at the promyelocyte/myelocyte stage) thus marking the formation of some neoantigen.
Immune Sensitization and Antibody Production: The host’s immune system detects this complex as non-self. In genetically predisposed individuals (see Pharmacogenomics below), this results in T-cell-mediated B-cell activation, which produces drug-dependent antibodies (DDABs). These are mostly IgG antibodies that are exclusively bound to the neutrophil membrane in the presence of the drug or its metabolite.
Effector Phase and Cell Destruction: The drug-DDAB complex on the neutrophil surface can initiate destruction through two main pathways: (i) Complement activation, leading to membrane attack complex formation and direct cell lysis; or
(ii) Fc receptor-mediated phagocytosis by macrophages in the spleen, liver, and bone marrow. The bone marrow often exhibits a characteristic ”maturation arrest,” where early precursors are present but development halts, reflecting immune attack on differentiating cells.
Direct Myelotoxic Agranulocytosis
This mechanism relies on the dose and is thus predictable. The original drug or its active forms are responsible for the direct blocking of crucial cellular processes occurring in fast-growing myeloid progenitor cells.
Alkylators such as cyclophosphamide, one of the chemotherapeutic agents, lead to apoptosis by cross-linking DNA, while antimetabolites such as methotrexate inhibit folate metabolism and also lead to cell death.
The DNA of the virus is getting shorter, and this is by the incorporation of the antiviral drug ganciclovir, which blocks the elongation of the DNA chain.
Another antibiotic, linezolid, causes myelosuppression that is temporarily reversible at the dose ¿28 days probably due to its effect on the mitochondria. The bone marrow in these cases is usually characterized by low cellularity, indicating a broad suppression of blood cell production.
The Role of Pharmacogenomics
Genetic predisposition is a key factor in the occurrence of immune-mediated DIAG. The existence of certain Human Leukocyte Antigen (HLA) alleles gives a strong indication of risk, meaning that the process of antigen presentation may become altered. For the case of antithyroid drug-induced agranulocytosis, the HLA-B*38:02 and HLA-DRB1*08:03 alleles are the main risk factors in Han Chinese and other Asian groups, with their odds being more than 20 (Chen et al., 2011). For clozapine, the associations with HLA- DQB1*05:02 and HLA-B*59:01 have been noted in various ethnicities. Apart from HLA, variations in the genes responsible for drug-metabolizing enzymes (such as NAT2, GST) may change the amount of reactive metabolite generated, thus affecting susceptibility of individual patients.
Clinical Presentation and Diagnostic Workup
The clinical manifestations point straight to the neutrophil deficiency. The onset of the disease in DIAG usually happens suddenly, and the patients shift from being in a good condition to being critically ill in a matter of a few hours.
Clinical Features
Systemic: High-grade fever (frequently above 39°C), chills, rigors, deep malaise, and tachycardia are almost always the first signs of the disease.
Mucocutaneous: These areas are the first to be infected because of their constant exposure to germs. The patient suffers from a severe sore throat, which may lead to necrotizing ulcerative pharyngitis or tonsillitis; painful oral and gingival ulcers; and perianal pain or cellulitis. Skin infections may appear as painful abscesses, cellulitis, or ecthyma gangrenosum (a characteristic lesion commonly associated with Pseudomonas aeruginosa).
Pulmonary: Cough, breathless, and pleuritic chest pain may signal pneumonia.
A Critical Paradox: In severe agranulocytosis, the classic signs of inflammation—rubor (redness), calor (heat), tumor (swelling), and dolor (pain)—may be greatly weakened or entirely missing at the site of infection. The throat may be examined and found to be surprisingly non-threatening, and a radiograph may show an infiltrate without any pus in the sputum. This gap between the severity of symptoms and the signs can dangerously prolong the diagnosis.
Diagnostic Algorithm
Complete blood count (CBC) with manual differential: This test is the main diagnostic test. It confirms severe neutropenia (ANC ¡500/µL) and also checks other blood cell types. In case of thrombocytopenia or anemia, the condition might point to a bigger problem in the marrow.
Meticulous medication history: It is very important to carry out a very thor- ough, time-wise examination of all prescribed, over-the-counter, herbal, and illegal drugs that were taken in the last three months. The history has to relate the symptoms’s start with the beginning of a new drug or a dosage change.
Blood cultures: A minimum of two sets (aerobic and anaerobic) must be taken from different venipuncture areas (and from the central lines, if there are any) before starting the antibiotic treatment.
Additional laboratory investigations:
Inflammatory markers: C-reactive protein (CRP) and procalcitonin always show high levels and are very useful for therapy monitoring.
Renal and hepatic function tests: To see if the organs are functioning properly and to determine the amount of antibiotic needed.
Viral serology/ PCR: For HIV, hepatitis viruses, EBV, CMV, parvovirus B19.
Autoimmune screen: Antinuclear antibody (ANA), rheumatoid factor, anti- neutrophil antibody (though sensitivity is variable).
Bone marrow aspiration and biopsy: The indications are:
Doubts about the diagnosis after non-invasive testing.
Pancytopenia.
Possible hidden blood malignancy (MDS, leukemia).
To separate immune-mediated (cellular with arrest) from myelotoxic (hypocellular) patterns.
Specialized testing (if available): The drug-dependent antineutrophil antibodies assays are very rare but have the definitive evidence and are performed only in very specialized reference laboratories.
Management: Evidence-Based Therapeutic Strategies
Management involves an emergency protocol of a multidisciplinary nature that is activated solely by suspicion.
Immediate Offending Agent’s Cessation
This is without doubt the most important, and therefore the first, intervention. All drugs deemed unnecessary should be stopped immediately. If there are no alternatives for the essential drug, a switch to another one that is chemically totally different is required.
Infection Management - Febrile Neutropenia Protocol
Risk Stratification: Patients are separated into two groups; one is the high-risk group, necessitating hospitalization, where the expected neutropenia is ¿7 days, ANC 100/L, huge comorbidities and unstable vital signs.
Empirical Antibiotic Therapy: The treatment has to be started within 60 minutes from the moment when a patient with febrile neutropenia comes in for treatment according to the guidelines. The recommendations suggest monotherapy with an anti-pseudomonal beta-lactam antibiotic:
Piperacillin-tazobactam
Cefepime
A carbapenem (meropenem, imipenem-cilastatin)
Gram-Positive Coverage (e.g., Vancomycin) is given empirically in addition to the treatment if: there is a suspicion of catheter-related infection, the patient is known to be colonized with MRSA, he/she has unstable blood pressure or there is a skin/soft tissue infection.
Antifungal Therapy: An echinocandin (caspofungin, micafungin) or a mold- active azole (voriconazole, isavuconazole) is added if fever persists after 4-7 days of broad-spectrum antibiotics, or if imaging/clinical findings suggest invasive fungal infection (e.g., sinusitis, nodular lung lesions).
Therapy is customized as soon as culture results and sensitivities are known. Antibiotics are usually continued until ANC is 500/µL and the patient has been afebrile for at least 48 hours.
Granulocyte Colony-Stimulating Factor (G-CSF)
G-CSF (filgrastim, lenograstim) or (pegfilgrastim) a long-acting pegylated form, is the standard treatment in DIAG. The drug works by enhancing the release of neutrophils from the marrow through stimulating the proliferation and differentiation of myeloid progenitors.
Evidence: Andr´es et al. (2018) meta-analysis combined the data from RCTs and cohort studies and showed that G-CSF significantly lessened the duration of neutropenia (by 2-4 days), the time to fever resolution, and the length of hospital stay. Though a statistically significant reduction in all-cause mortality is more challenging to prove in RCTs (because of the relatively low event rates), the neutrophil recovery acceleration is recognized as a surrogate endpoint that is very close to the infection-related mortality.
Consensus Recommendation: The use of G-CSF is advisable for the majority of patients with DIAG, especially if they are: ANC ¡100/µL, ¿65 years old, septic or have severe infections (pneumonia, deep tissue infection), or have other medical conditions (kidney disease, malnutrition). The usual dosage is 5 µg/kg/day subcutaneously until the ANC is above 1000/µL or shows a steady increase for 3 days in a row.
Supportive Care
Protective Isolation: Keeping the patient strictly isolated with strong hand sanitation, a single room if at all possible, and the exclusion of fresh flowers or standing water in order to lessen the risk of contacts with environmental fungi.
Mucosal Care: Very careful and complete oral hygiene using saline or chlorhexidine mouthwashes. Proper skin care routines that include daily bathing and thorough perianal cleaning.
Nutritional Support: Sufficient intake of calories and protein to maintain host defense and allow for recovery of the marrow.
Transfusions: Granulocyte transfusions are infrequently utilized and are only given to patients with infections that are life-threatening, resistant to maximal antimicrobial and G-CSF therapy for 48-72 hours, and where the use of granulocytes is justified despite the short half-life, logistical difficulties, and the risk of severe side effects (pulmonary infiltrates, febrile reactions).
DISCUSSION
The current evidence synthesized in this review shedding light over the established paradigms and the evolving frontiers in the understanding and management of agranulocytosis. The pivotal pharmacological drugs-induced mechanisms, especially the unforeseeable immune response, point out a very serious problem in today’s medicine i.e. the need to choose between therapeutic benefits or the chances of unpredictable, major toxicity.
The Pathogenetic Dichotomy and Its Clinical Implications
The very clear border between immune-mediated and direct myelotoxic mechanisms has wide-ranging clinical consequences. Immune-mediated DIAG, with its genetic causes and non-dependency on doses, is the case where the individual’s immune system fails to tolerate a drug metabolite. This is the reason why it can occur even when the patient is on a drug for months without any adverse reactions. On the contrary, myelotoxic agranulocytosis is a pharmacokinetic/pharmacodynamic phenomenon, often predictable and manageable through adjustments in the dosage or by taking treatment breaks, as in oncology. It is recognizing this dichotomy that assists effective management (like the pointlessness of just reducing the dose of an immune-inducing drug) and putting up preventive measures.
Pharmacogenomics: From Association to Prevention
The HLA association that has been revealed for antithyroid drugs and clozapine has become a milestone in the personalized treatment of adverse drug reactions. In Taiwan, drug carbimazole is prescribed only to those patients who have been previously screened for HLA-B38:02 and HLA-DRB108:03, resulting in a noticeable decrease of associated agranulocytosis (Chen et al., 2011). HLA testing for clozapine is not yet a standard procedure in the world, but it is a hotly discussed and researched topic. There are barriers to the screening implementation: being economical with low-incidence populations, the risk being polygenic (likely many genes involve), and the affiliation between ethnic and allele frequencies. The exploration of the genetic landscape for other high-risk drugs along with developing a cost-effective screening panel will be the mainstay of future research in this area.
G-CSF: Resolving Remaining Questions
The argument for G-CSF usage in DIAG is very convincing, but still, some questions remain. The first one is the best length of treatment: extending until ANC crosses 1000/L is the prevailing rule, yet some suggest a shorter one when a clear upward trend is detected. Secondly, the agent’s choice: daily filgrastim permits dose adjustment but necessitates daily injections; a one-time pegfilgrastim dose is easier but might cause too much neutrophil elevation (leukocytosis) for a long time and is not officially approved for this use. It is also true that large, prospective comparative studies are lacking. A third question is cost-effectiveness: in poor areas or among patients with mild cases (ANC 200-500/L, no fever), the potential advantage has to be put against the huge price of growth factors.
Prognosis and Evolving Mortality Trends
The historical death rates resulting from agranulocytosis were more than 20%. Contem- porary records from hospitals specializing in such conditions indicate that the rates are between 5% and 10% (Andr`es et al., 2019). This change in numbers is due to better and more supportive care: quick diagnosis, very strong anti-microbial treatment, and the routine use of G-CSF. However, still, in some patients, the mortality rate is too high to be acceptable: older patients (over 75 years of age), patients with an ANC that stays under 100/L usually, and also those who suffer from septic shock, kidney failure, or invasive fungal infections. The majority of the deaths are due to septic shock and multiple-organ failure, and then hemorrhage in the case of complicating thrombocytopenia.
Challenges and Future Directions
Improved Pharmacovigilance and Predictive Tools: Pre-marketing trials have a drawback in that they are always likely to produce a positive result for the very common side effects and might miss the rarer ones like agranulocytosis. It is important to get good post-marketing surveillance going, and one way of doing that would be the use of large electronic health record databases and artificial intelligence for signal detection. While the in vitro diagnosis of drug-induced idiosyncrasy using patient-derived immune cells or stem cells may be a promising goal it still remains as such and not realized yet.
Patient Education and Empowerment: Education is a critical preventive mea- sure for patients who are receiving treatment with high-risk drugs such as clozapine and antithyroid medications. They should be told to promptly report any infec- tion symptoms, such as fever and sore throat, and to understand the importance of regular blood tests. This mutual responsibility can result in quicker treatment and intervention.
Management of Refractory Cases: There is a need for research into novel therapies for patients who do not respond to G-CSF. This research could involve the use of other growth factors (like GM-CSF), immunosuppressive treatments (like steroids, IVIG) in cases of immune-mediated destruction that have been proved, or novel agents that specifically target apoptotic pathways in the bone marrow.
Global Health Considerations: In different parts of the world, dipyrone (metami- zole) and chloramphenicol, which have a significant risk of causing agranulocytosis, are still widely available without a prescription. Public health measures to limit access to these drugs combined with educating health care providers on safer alter- natives are crucial to cutting down the global burden of this disease.
CONCLUSION
Agranulocytosis is a very serious and life-threatening condition that can arise quickly in the hematological area. It is still a very strong and urgent emergency in this area. Drug-tampering toxicity stays one of its main causes, though. The most outstanding case is in drugs that work through the immune system where the reactions are wrongly termed idiosyncratic. The case occurs when the drug is being metabolized, the patient has a genetic predisposition, and the immune system is activated simultaneously - a very poor combination indeed. The clinical picture shows a sudden rise in temperature and infection in such a heavily neutropenic patient. A simple CBC will confirm the diagnosis but this will still require the same effort as a detective to know the patient’s medication history.
Today’s treatment that has made it much easier for the patient to recover is built on three mainstays: (1) stopping the drug thought to be causing the problem immediately,
(2) starting empirical, broad-spectrum antimicrobial therapy as per febrile neutropenia protocols quickly, and (3) administering G-CSF to boost marrow recovery and reduce the duration of susceptibility. Supportive care along with infection control measures is the basis of it all.
The future of agranulocytosis is prevention and personalization. The combination of pharmacogenomic screening prior to prescribing high-risk drugs is one aspect that directly addresses prevention of such drugs leading to patients’ neutropenic conditions. Certainly, better pharmacovigilance systems and empirical predictive in vitro models will open the safer route during drug development for the latter part of the process. For medical professionals, constant alertness, a very pronounced positivity of the case, and through patient education will remain the most powerful measures in lessening the mortality and morbidity arising from such severest drug adverse reactions. As the population lives longer, and more patients have to take multiple medicines, the understanding of agranulocytosis as a clinical condition will only grow along with the needs for quick diagnosis and effective management.
REFERENCES
· Alvir, Jos´e Ma. J., et al. ”Clozapine-Induced Agranulocytosis: Incidence and Risk Factors in the United States.” New England Journal of Medicine, vol. 329, no. 3, 1993, pp. 162-67.
· Andr`es, Emmanuel, et al. ”Agranulocytosis: Update 2022.” Journal of Clinical Medicine, vol. 11, no. 20, 2022, p. 6065.
· Andr`es, Emmanuel, et al. ”Clinical Presentation and Management of Drug-Induced Agranulocytosis.” Expert Review of Hematology, vol. 4, no. 2, 2011, pp. 143-51.
· Andr`es, Emmanuel, et al. ”The Use of Colony-Stimulating Factors in Drug-Induced Agranulocytosis: A Review of the Literature.” Current Drug Safety, vol. 13, no. 2, 2018, pp. 83-89.
· Andr`es, Emmanuel, et al. ”Non-Chemotherapy Drug-Induced Agranulocytosis: Ex- perience of the Strasbourg Teaching Hospital (2000-2018) and Review of the Liter- ature.” Journal of Clinical Medicine, vol. 8, no. 9, 2019, p. 1358.
· Chen, Pei-Lung, et al. ”Genetic Determinants of Antithyroid Drug-Induced Agran- ulocytosis.” Current Drug Safety, vol. 6, no. 1, 2011, pp. 33-38.
· Curtis, Brian R. ”Drug-Induced Immune Neutropenia/ Agranulocytosis.” Immuno- hematology, vol. 30, no. 2, 2014, pp. 95-101.
· Freifeld, Alison G., et al. ”Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Dis- eases Society of America.” Clinical Infectious Diseases, vol. 52, no. 4, 2011, pp. e56-e93.
· Kaufman, David W., and Padmini Kogulan. ”Drug-Induced Agranulocytosis and Other Cytopenias: Epidemiology and Mechanisms.” Drug-Induced Hematologic Disorders, edited by James O. Armitage and David W. Kaufman, Humana Press, 2001, pp. 1-28.
· Lally, John, et al. ”The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review.” Journal of Psychopharmacology, vol. 32, no. 8, 2018, pp. 874-85.
· Strom, Brian L., et al. ”Pharmacoepidemiology of Drug-Induced Agranulocytosis: The International Agranulocytosis and Aplastic Anemia Study.” Pharmacoepidemi- ology and Drug Safety, vol. 21, no. S2, 2012, pp. 158-64.
· Walsh, Thomas J., et al. ”Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever.” New England Journal of Medicine, vol. 346, no. 4, 2002, pp. 225-34.